Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BIMEKIZUMAB Cause Product distribution issue? 52 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 52 reports of Product distribution issue have been filed in association with BIMEKIZUMAB (Bimzelx). This represents 2.1% of all adverse event reports for BIMEKIZUMAB.

52
Reports of Product distribution issue with BIMEKIZUMAB
2.1%
of all BIMEKIZUMAB reports
1
Deaths
12
Hospitalizations

How Dangerous Is Product distribution issue From BIMEKIZUMAB?

Of the 52 reports, 1 (1.9%) resulted in death, 12 (23.1%) required hospitalization, and 1 (1.9%) were considered life-threatening.

Is Product distribution issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BIMEKIZUMAB. However, 52 reports have been filed with the FAERS database.

What Other Side Effects Does BIMEKIZUMAB Cause?

Psoriatic arthropathy (615) Psoriasis (400) Drug ineffective (293) Inappropriate schedule of product administration (238) Injection site pain (225) Product dose omission issue (163) Off label use (160) Oral candidiasis (146) Fatigue (138) Therapy interrupted (138)

What Other Drugs Cause Product distribution issue?

LENALIDOMIDE (858) CERTOLIZUMAB PEGOL (403) SECUKINUMAB (340) RUXOLITINIB (301) HUMAN IMMUNOGLOBULIN G (279) POMALIDOMIDE (254) RELUGOLIX (243) VEDOLIZUMAB (150) PIMAVANSERIN (134) TEDUGLUTIDE (132)

Which BIMEKIZUMAB Alternatives Have Lower Product distribution issue Risk?

BIMEKIZUMAB vs BIMEKIZUMAB-BKZX BIMEKIZUMAB vs BINIMETINIB BIMEKIZUMAB vs BIOFLAVONOIDS BIMEKIZUMAB vs BIOTIN BIMEKIZUMAB vs BIPERIDEN

Related Pages

BIMEKIZUMAB Full Profile All Product distribution issue Reports All Drugs Causing Product distribution issue BIMEKIZUMAB Demographics